{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:42:04Z","timestamp":1794271324611,"version":"4.9.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP210158"],"award-info":[{"award-number":["RP210158"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-65897-4","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T14:38:39Z","timestamp":1770215919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7505-7107","authenticated-orcid":false,"given":"Chiou-Tsun","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ibanez-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Teis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiro","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Valkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5181-2696","authenticated-orcid":false,"given":"Peter J.","family":"Chockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes Asenath Jimenez","family":"Madrigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4335-0644","authenticated-orcid":false,"given":"Giedre","family":"Krenciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7178-8163","authenticated-orcid":false,"given":"Maksim","family":"Mamonkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"65897_CR1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fonc.2020.00697","volume":"10","author":"S Mardiana","year":"2020","unstructured":"Mardiana, S. & Gill, S. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front. Oncol. 10, 697 (2020).","journal-title":"Front. Oncol."},{"key":"65897_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou, A. J., Chen, L. C. & Chen, Y. Y. Navigating CAR-T cells through the solid-tumour microenvironment. Nat. Rev. Drug Discov. 20, 531\u2013550 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"65897_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang, J. et al. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J. Hematol. Oncol. 11, 7 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"65897_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz3223","volume":"6","author":"SE Lindner","year":"2020","unstructured":"Lindner, S. E., Johnson, S. M., Brown, C. E. & Wang, L. D. Chimeric antigen receptor signaling: functional consequences and design implications. Sci. Adv. 6, eaaz3223 (2020).","journal-title":"Sci. Adv."},{"key":"65897_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20\u201328 (2018).","journal-title":"Nat. Med."},{"key":"65897_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702\u2013723 (2020).","journal-title":"Cancer Discov."},{"key":"65897_CR7","doi-asserted-by":"crossref","unstructured":"Hazini, A., Fisher, K., Seymour, L. Deregulation of HLA-I in cancer and its central importance for immunotherapy. J. Immunother. Cancer 9, e002899 (2021).","DOI":"10.1136\/jitc-2021-002899"},{"key":"65897_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"65897_CR9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","volume":"4","author":"E Zah","year":"2016","unstructured":"Zah, E., Lin, M. Y., Silva-Benedict, A., Jensen, M. C. & Chen, Y. Y. T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol. Res. 4, 498\u2013508 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"65897_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"65897_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-018-0020-8","volume":"18","author":"G Gaud","year":"2018","unstructured":"Gaud, G., Lesourne, R. & Love, P. E. Regulatory mechanisms in T cell receptor signalling. Nat. Rev. Immunol. 18, 485\u2013497 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"65897_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3389\/fimmu.2018.00307","volume":"9","author":"A Kabanova","year":"2018","unstructured":"Kabanova, A., Zurli, V. & Baldari, C. T. Signals controlling lytic granule polarization at the cytotoxic immune synapse. Front. Immunol. 9, 307 (2018).","journal-title":"Front. Immunol."},{"key":"65897_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley, A. M. et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 615, 507\u2013516 (2023).","journal-title":"Nature"},{"key":"65897_CR14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi, K. et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. cancer 2, 904\u2013918 (2021).","journal-title":"Nat. cancer"},{"key":"65897_CR15","doi-asserted-by":"publisher","first-page":"a005512","DOI":"10.1101\/cshperspect.a005512","volume":"2","author":"L Balagopalan","year":"2010","unstructured":"Balagopalan, L., Coussens, N. P., Sherman, E., Samelson, L. E. & Sommers, C. L. The LAT story: a tale of cooperativity, coordination, and choreography. Cold Spring Harb. Perspect. Biol. 2, a005512 (2010).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"65897_CR16","doi-asserted-by":"publisher","first-page":"23355","DOI":"10.1074\/jbc.M000404200","volume":"275","author":"W Zhang","year":"2000","unstructured":"Zhang, W. et al. Association of Grb2, Gads, and phospholipase C-gamma 1 with phosphorylated LAT tyrosine residues. Effect of LAT tyrosine mutations on T cell angigen receptor-mediated signaling. J. Biol. Chem. 275, 23355\u201323361 (2000).","journal-title":"J. Biol. Chem."},{"key":"65897_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1189\/jlb.0404262","volume":"77","author":"C Sandoval-Montes","year":"2005","unstructured":"Sandoval-Montes, C. & Santos-Argumedo, L. CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines. J. Leukoc. Biol. 77, 513\u2013521 (2005).","journal-title":"J. Leukoc. Biol."},{"key":"65897_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","volume":"21","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva, D. et al. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. Cell Rep. 21, 17\u201326 (2017).","journal-title":"Cell Rep."},{"key":"65897_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","volume":"6","author":"M Mamonkin","year":"2018","unstructured":"Mamonkin, M. et al. Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies. Cancer Immunol. Res. 6, 47\u201358 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"65897_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/CJI.0b013e3181adaff1","volume":"32","author":"K Mihara","year":"2009","unstructured":"Mihara, K. et al. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. J. Immunother. 32, 737\u2013743 (2009).","journal-title":"J. Immunother."},{"key":"65897_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","volume":"12","author":"X Han","year":"2019","unstructured":"Han, X., Wang, Y., Wei, J. & Han, W. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J. Hematol. Oncol. 12, 128 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"65897_CR22","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","volume":"25","author":"H Tashiro","year":"2017","unstructured":"Tashiro, H. et al. Treatment of acute myeloid leukemia with t cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1. Mol. Ther. J. Am. Soc. Gene Ther. 25, 2202\u20132213 (2017).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"65897_CR23","doi-asserted-by":"crossref","unstructured":"Ataca Atilla, P. et al. Modulating TNFalpha activity allows transgenic IL15-expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J. Immunother. Cancer 8, e001229 (2020).","DOI":"10.1136\/jitc-2020-001229"},{"key":"65897_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2021.102514","volume":"101","author":"HC Lee","year":"2022","unstructured":"Lee, H. C., Deng, Q. W. & Zhao, Y. J. The calcium signaling enzyme CD38 - a paradigm for membrane topology defining distinct protein functions. Cell calcium 101, 102514 (2022).","journal-title":"Cell calcium"},{"key":"65897_CR25","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0092-8674(02)01082-6","volume":"111","author":"GC Churchill","year":"2002","unstructured":"Churchill, G. C. et al. NAADP mobilizes Ca(2+) from reserve granules, lysosome-related organelles, in sea urchin eggs. Cell 111, 703\u2013708 (2002).","journal-title":"Cell"},{"key":"65897_CR26","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.1074\/jbc.RA118.002113","volume":"293","author":"C Fang","year":"2018","unstructured":"Fang, C. et al. CD38 produces nicotinic acid adenosine dinucleotide phosphate in the lysosome. J. Biol. Chem. 293, 8151\u20138160 (2018).","journal-title":"J. Biol. Chem."},{"key":"65897_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101297","volume":"4","author":"J Ibanez","year":"2023","unstructured":"Ibanez, J. et al. GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells. Cell Rep. Med. 4, 101297 (2023).","journal-title":"Cell Rep. Med."},{"key":"65897_CR28","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/mt.2015.199","volume":"24","author":"G Krenciute","year":"2016","unstructured":"Krenciute, G. et al. Characterization and functional analysis of scfv-based chimeric antigen receptors to redirect T cells to IL13Ralpha2-positive glioma. Mol. Ther. J. Am. Soc. Gene Ther. 24, 354\u2013363 (2016).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"65897_CR29","doi-asserted-by":"publisher","first-page":"e0197823","DOI":"10.1371\/journal.pone.0197823","volume":"13","author":"BN Ostendorf","year":"2018","unstructured":"Ostendorf, B. N., Flenner, E., Florcken, A. & Westermann, J. Phenotypic characterization of aberrant stem and progenitor cell populations in myelodysplastic syndromes. PloS ONE 13, e0197823 (2018).","journal-title":"PloS ONE"},{"key":"65897_CR30","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","volume":"110","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen, A. et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110, 2659\u20132666 (2007).","journal-title":"Blood"},{"key":"65897_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1172\/JCI75876","volume":"125","author":"C Arber","year":"2015","unstructured":"Arber, C. et al. Survivin-specific T cell receptor targets tumor but not T cells. J. Clin. Investig. 125, 157\u2013168 (2015).","journal-title":"J. Clin. Investig."},{"key":"65897_CR32","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton, L. V. et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc. Natl. Acad. Sci. USA 113, E7788\u2013E7797 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65897_CR33","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute, G. et al. Transgenic expression of IL15 improves antiglioma activity of IL13Ralpha2-CAR T cells but results in antigen loss variants. Cancer Immunol. Res. 5, 571\u2013581 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"65897_CR34","doi-asserted-by":"crossref","unstructured":"Zhou, Y. et al. Interleukin 15 in cell-based cancer immunotherapy. Int. J. Mol. Sci. 23, 7311 (2022).","DOI":"10.3390\/ijms23137311"},{"key":"65897_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh1962","volume":"13","author":"A Katsarou","year":"2021","unstructured":"Katsarou, A. et al. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Sci. Transl. Med. 13, eabh1962 (2021).","journal-title":"Sci. Transl. Med."},{"key":"65897_CR36","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","volume":"41","author":"S Haubner","year":"2023","unstructured":"Haubner, S. et al. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer cell 41, 1871\u20131891 e1876 (2023).","journal-title":"Cancer cell"},{"key":"65897_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1256491","volume":"14","author":"M Kalaitsidou","year":"2023","unstructured":"Kalaitsidou, M. et al. Signaling via a CD28\/CD40 chimeric costimulatory antigen receptor (CoStAR), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes. Front. Immunol. 14, 1256491 (2023).","journal-title":"Front. Immunol."},{"key":"65897_CR38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1158\/2326-6066.CIR-21-0307","volume":"10","author":"B Omer","year":"2022","unstructured":"Omer, B. et al. A costimulatory CAR improves TCR-based cancer immunotherapy. Cancer Immunol. Res. 10, 512\u2013524 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"65897_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701704","volume":"12","author":"Y Dinur-Schejter","year":"2021","unstructured":"Dinur-Schejter, Y., Zaidman, I., Mor-Shaked, H. & Stepensky, P. The clinical aspect of adaptor molecules in T cell signaling: lessons learnt from inborn errors of immunity. Front. Immunol. 12, 701704 (2021).","journal-title":"Front. Immunol."},{"key":"65897_CR40","doi-asserted-by":"publisher","first-page":"29588","DOI":"10.1074\/jbc.M102221200","volume":"276","author":"J Lin","year":"2001","unstructured":"Lin, J. & Weiss, A. Identification of the minimal tyrosine residues required for linker for activation of T cell function. J. Biol. Chem. 276, 29588\u201329595 (2001).","journal-title":"J. Biol. Chem."},{"key":"65897_CR41","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020104730","volume":"39","author":"R Dong","year":"2020","unstructured":"Dong, R. et al. Rewired signaling network in T cells expressing the chimeric antigen receptor (CAR). EMBO J. 39, e104730 (2020).","journal-title":"EMBO J."},{"key":"65897_CR42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","volume":"270","author":"NW van de Donk","year":"2016","unstructured":"van de Donk, N. W. et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol. Rev. 270, 95\u2013112 (2016).","journal-title":"Immunol. Rev."},{"key":"65897_CR43","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","volume":"1","author":"T Casneuf","year":"2017","unstructured":"Casneuf, T. et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 1, 2105\u20132114 (2017).","journal-title":"Blood Adv."},{"key":"65897_CR44","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","volume":"7","author":"T Glisovic-Aplenc","year":"2023","unstructured":"Glisovic-Aplenc, T. et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 7, 4418\u20134430 (2023).","journal-title":"Blood Adv."},{"key":"65897_CR45","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/ni.3392","volume":"17","author":"VT Chang","year":"2016","unstructured":"Chang, V. T. et al. Initiation of T cell signaling by CD45 segregation at \u2018close contacts. Nat. Immunol. 17, 574\u2013582 (2016).","journal-title":"Nat. Immunol."},{"key":"65897_CR46","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/ni1369","volume":"7","author":"SJ Davis","year":"2006","unstructured":"Davis, S. J. & van der Merwe, P. A. The kinetic-segregation model: TCR triggering and beyond. Nat. Immunol. 7, 803\u2013809 (2006).","journal-title":"Nat. Immunol."},{"key":"65897_CR47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva, D. et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130, 285\u2013296 (2017).","journal-title":"Blood"},{"key":"65897_CR48","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/nmeth.3543","volume":"12","author":"MA Moreno-Mateos","year":"2015","unstructured":"Moreno-Mateos, M. A. et al. CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. Nat. methods 12, 982\u2013988 (2015).","journal-title":"Nat. methods"},{"key":"65897_CR49","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin, M., Rouce, R. H., Tashiro, H. & Brenner, M. K. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 126, 983\u2013992 (2015).","journal-title":"Blood"},{"key":"65897_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-1-0716-0146-4_8","volume":"2086","author":"F Mo","year":"2020","unstructured":"Mo, F. & Mamonkin, M. Generation of chimeric antigen receptor T cells using gammaretroviral vectors. Methods Mol. Biol. 2086, 119\u2013130 (2020).","journal-title":"Methods Mol. Biol."},{"key":"65897_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2024.103422","volume":"5","author":"J Ibanez","year":"2024","unstructured":"Ibanez, J. et al. Protocol for live-cell imaging of immune synapse formation and activation of CAR T cells against cancer cells. STAR Protoc. 5, 103422 (2024).","journal-title":"STAR Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65897-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65897-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65897-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:05:53Z","timestamp":1770221153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65897-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["65897"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65897-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.M. is a co-founder with equity and an independent director at March Biosciences. M.M. receives fees from Allogene, Beam Therapeutics, Fate Therapeutics, March Biosciences, and Curie.bio. M.M. receives research support from Fate Therapeutics and March Biosciences and honoraria from Amgen and Galapagos NV and serves on the advisory board of NKILT Therapeutics and March Biosciences. M.M., N.W., G.K. and C.T.T. have patent applications in the field of engineered cell therapies. An up to date declaration of interests for the listed authors can be found at\n                      \n                      . The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1349"}}